Transcriptomic profiling reveals that OX40 and OX40L expression is variable between tumors and that the pattern of high OX40 and low OX40L, which might theoretically be most amenable to OX40 agonist compounds, occurs in only 17% of cancer patients, most commonly in lung and breast cancers. Here, TNFRSF4 is linked to cancer.